chufangao/CTO huggingface dataset:
Clinical trial NCT03742349: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Official title: A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This was a sponsor decision and was not a consequence of any safety concern
Enrollment: 64.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-01-31
Primary completion date: 2023-02-06
Completion date: 2023-02-06
Plan to share individual participant data: NO
Clinical trial NCT04325802: Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone
Official title: Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone and Effects on Skin Circadian Rhythm
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Covid-19 pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-12-31
Primary completion date: 2024-06-30
Completion date: 2024-06-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05032950: Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants
Official title: COVID-19: A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY PARTICIPANTS.
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-09-17
Primary completion date: 2021-12-09
Completion date: 2021-12-09
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02664155: Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Official title: Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Acronym: VERDICT
Sponsor: Centre Hospitalier Universitaire de Saint Etienne (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: recruiting difficulties
Enrollment: 203.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-10-19
Primary completion date: 2021-11-30
Completion date: 2022-05-30
Plan to share individual participant data: NO
Clinical trial NCT05103826: A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
Official title: A Phase I Study to Evaluate Safety 、Tolerability 、 Pharmacokinetics and Efficacy of SHR6390 in Combination With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor R \& D Strategy Adjustment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-10-25
Primary completion date: 2023-06-15
Completion date: 2023-06-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02495922: A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
Official title: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
Acronym: GMMG-HD6
Sponsor: University of Heidelberg Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 564.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-06-30
Primary completion date: 2021-06-24
Completion date: 2021-06-24
Clinical trial NCT03655444: Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Official title: A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Provider of drug decided to discontinue study.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-29
Primary completion date: 2020-08-24
Completion date: 2020-08-24
Plan to share individual participant data: NO
Clinical trial NCT03776864: Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Official title: A Phase II Trial of Umbralisib and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Company providing drug terminated their oncology program
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-09-26
Primary completion date: 2021-09-14
Completion date: 2021-09-14
Plan to share individual participant data: NO
Clinical trial NCT05298202: The Influence of Capsaicin Gel During Exercise Within the Heat
Official title: The Influence of Topical Capsaicin on Thermoregulatory and Perceptual Outcomes During Exercise Within the Heat
Sponsor: University of Nebraska (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-25
Primary completion date: 2022-10-01
Completion date: 2022-10-01
Plan to share individual participant data: NO
Clinical trial NCT03807882: Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
Official title: Comparison of Maintenance ECT Versus Clozapine on Psychopathology and Cerebral Hemodynamics in Treatment-resistant Schizophrenia: A Randomized Controlled Trial
Sponsor: All India Institute of Medical Sciences, Bhubaneswar (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-01
Primary completion date: 2020-05-31
Completion date: 2020-06-30
Clinical trial NCT03908333: High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Official title: Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Request to close per funding sponsor. Site not moving forward with trial.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-01
Primary completion date: 2022-05-01
Completion date: 2023-05-01
Clinical trial NCT01285817: A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours.
Official title: A Phase II Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing Solid Tumours.
Acronym: SFCE METRO 01
Sponsor: Assistance Publique Hopitaux De Marseille (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 79.0 (ACTUAL)
Number of arms: 1.0
Start date: 2011-01-12
Primary completion date: 2015-09-11
Completion date: 2023-03-09
Clinical trial NCT02657356: Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
Official title: A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Exposure of these high-risk patients to clinic or in-person visits during the pandemic presented an unacceptable risk to their health
Enrollment: 202.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-10-04
Primary completion date: 2020-05-07
Completion date: 2020-05-07
Baseline population: Intent to treat (ITT) population (all randomized patients categorized by their assigned treatment group regardless of treatment exposure)
Plan to share individual participant data: YES
IPD sharing description: In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Clinical trial NCT03457025: Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome
Official title: Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome
Sponsor: NYU Langone Health (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: lack of enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-31
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Only as pertains to study results, will be shared only during publication.
IPD time frame: Immediately following publication. No end date.
IPD access criteria: Only shared with publication.
Clinical trial NCT01841359: Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Official title: Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Sponsor: Joslin Diabetes Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-02-02
Primary completion date: 2016-07-31
Completion date: 2022-02-08
Baseline population: Analysis is based upon 14 participants who completed the protocol.
Clinical trial NCT05489679: A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Sponsor: Accutar Biotechnology Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Voluntarily terminate the study since the sponsor's development strategy was adjusted.
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-10-01
Primary completion date: 2023-09-28
Completion date: 2023-09-28
Clinical trial NCT04397510: Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury
Official title: Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury
Sponsor: Frederick Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
Clinical trial NCT04842747: VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
Official title: Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).
Acronym: VERU-111
Sponsor: Veru Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 204.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-18
Primary completion date: 2022-07-06
Completion date: 2022-07-06
Plan to share individual participant data: NO
Clinical trial NCT04332107: Azithromycin for COVID-19 Treatment in Outpatients Nationwide
Official title: Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19
Acronym: ACTION
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Futility
Enrollment: 263.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-22
Primary completion date: 2021-03-16
Completion date: 2021-03-30
Baseline population: A single participant in the Azithromycin group did not have baseline symptom information.
Limitations and caveats: This trial was terminated early by the DSMC for futility on March 16, 2021. Therefore, we were not able to complete the analysis for all secondary outcomes because funds were returned to the sponsor following the completion of the study.~Please note that the number of participants varies by period as participants could opt to complete some questionnaires but not others. For example, a participant may skip the day 3 questionnaire, but complete the day 14 questionnaire.
Plan to share individual participant data: YES
Clinical trial NCT04127721: Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
Official title: Itacitinib to Prevent Graft Versus Host Disease
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: 0 ACTUAL Enrollment must have Overall Recruitment Status
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-22
Primary completion date: 2020-09-22
Completion date: 2020-09-22
Clinical trial NCT04549285: Infusions of Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome
Official title: A Phase I Pilot Study of the Safety of Infusions of Allogeneic Human Cord Tissue Mesenchymal Stromal Cells in Children With Multisystem Inflammatory Syndrome in Children (MIS-C)
Acronym: MISTIC
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: No accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-12
Primary completion date: 2022-02-01
Completion date: 2022-02-01
Plan to share individual participant data: NO
Clinical trial NCT03752138: TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
Official title: Phase I Study of TK216 in Patients With Relapsed and Refractory Leukemias
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: The supporting pharamceutical company elected not to pursue this study at this time.
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-03-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT04384809: Platelet Rich Plasma Injection vs Percutaneous Tenotomy for Common Extensor Tendinopathy
Official title: Comparison of Leukocyte-rich Platelet Rich Plasma Injection to Percutaneous Tenotomy in the Treatment of Chronic Common Extensor Tendinopathy
Sponsor: University Hospitals Cleveland Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-01
Primary completion date: 2023-05-01
Completion date: 2023-05-01
Clinical trial NCT03066440: Double Blinded Randomized Control Trial of Types of IVF in Children With DKA
Official title: A Single-center Randomized Double Blinded Control Trial of Intravenous Fluid Content in Children With Diabetic Ketoacidosis Admitted to the Pediatric Intensive Care Unit
Sponsor: State University of New York at Buffalo (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Shortage of potassium acetate for study intravenous fluids
Enrollment: 53.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-09-01
Primary completion date: 2024-03-18
Completion date: 2024-03-18
Plan to share individual participant data: NO
Clinical trial NCT03999515: Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Official title: Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated due to slow accrual
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-27
Primary completion date: 2021-06-06
Completion date: 2021-06-06
Plan to share individual participant data: NO
Clinical trial NCT03291938: IACS-010759 in Advanced Cancers
Official title: A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 29.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-11-13
Primary completion date: 2020-11-23
Completion date: 2020-11-23
Clinical trial NCT04890379: Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage
Official title: Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage
Sponsor: Xuanwu Hospital, Beijing (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: There are no sufficient patients in the hospital.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT05427981: Anti-suicidal Effects of Buprenorphine In Depressed Individuals
Official title: Functional Brain Mechanisms Underlying the Anti-Suicidal Effects of Low-dose Buprenorphine in Major Depression
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will not resume recruitment after the resumption of research.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-10
Primary completion date: 2024-01-14
Completion date: 2024-01-14
Plan to share individual participant data: NO
Clinical trial NCT04412876: Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study
Official title: Comparisons of the Impact of Duloxetine Versus Imipramine on Therapeutic Efficacy, Psychological Distress, Sexual Function, Urethral and Bladder Wall Structure and Blood Flow in Women With Stress Urinary Incontinence: a Randomized Controlled Study
Sponsor: Far Eastern Memorial Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Failed to pass the Ministry of Science and Technology.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-31
Primary completion date: 2020-05-31
Completion date: 2021-06-03
Plan to share individual participant data: NO
Clinical trial NCT04968158: Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back Pain
Official title: Confirmatory Efficacy and Safety Study of the Fixed-dose Combination of Etoricoxib / Tramadol Versus Acetaminophen / Tramadol for the Management of Acute Low Back Pain.
Sponsor: Laboratorios Silanes S.A. de C.V. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 124.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-29
Primary completion date: 2022-03-15
Completion date: 2022-04-10
Plan to share individual participant data: NO
Clinical trial NCT01492582: Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
Official title: Quadrivalent Human Papillomavirus (qHPV) Vaccine in Cancer Survivors: Cross Sectional Survey and Phase II Open-Label Vaccine Trial
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 1499.0 (ACTUAL)
Number of arms: 1.0
Start date: 2012-07-31
Primary completion date: 2019-02-08
Completion date: 2020-07-20
Baseline population: Participants who consented to the study.
Clinical trial NCT02957682: Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 2176.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-11-02
Primary completion date: 2020-03-05
Completion date: 2020-03-05
Baseline population: Safety population (SAF) included all participants randomized and exposed to at least one dose of study drug, regardless of the amount of treatment administered.
Clinical trial NCT04894994: FLX475 in Combination With Ipilimumab in Advanced Melanoma
Official title: Phase 2 Study of FLX475 in Combination With Ipilimumab in Advanced Melanoma
Sponsor: RAPT Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Change in clinical landscape
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-03
Primary completion date: 2022-09-13
Completion date: 2022-09-13
Limitations and caveats: The study was terminated early due to changes in the treatment landscape of melanoma that have occurred since the initiation of the study, leading to small numbers of subjects analyzed.
Clinical trial NCT04839237: The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients
Official title: The Effect and the Pharmacogenomics Study of Liraglutide in Obese Patients
Sponsor: Xiangya Hospital of Central South University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The sponsor decides withdrawn this study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-01
Primary completion date: 2020-12-01
Completion date: 2021-12-01
Clinical trial NCT02758366: Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
Official title: An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)
Sponsor: Meyer Children's Hospital IRCCS (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was terminated due to high heterogeneity of enrolled patients
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-02-29
Primary completion date: 2020-01-16
Completion date: 2020-01-16